![]() |
New FDA Approval: Fycompa® to Treat Seizures...
March 1, 2013 - Clinical , Featured By: Bhavini Shah, PharmD Candidate c/o 2013 – Fycompa® (perampanel) has received the U.S. Food and Drug Administration (FDA) approval for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.1 The drug, manufactured by Eisai Inc., is already approved for use in Iceland,… |
![]() |
FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications. This… |
![]() |
Liraglutide (Victoza®) for Type 2 Diabetes Mellitus...
February 1, 2013 - Clinical , Featured By: Miriam Maltz, PharmD Candidate c/o 2013, AMSCOP, Long Island University – Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is pursuant to insulin resistance, defects in insulin secretion, or both1. Chronic hyperglycemia is associated with detrimental effects on various organ systems that can increase mortality and impact the patient’s… |
![]() |
Rho Chi Beta Delta Chapter Induction Ceremony...
February 1, 2013 - Events By: Bethsy Jacob, PharmD Candidate c/o 2013 – On January 24, 2013, Rho Chi Beta Delta Chapter successfully conducted its annual induction ceremony, welcoming forty-four new members into the chapter. Membership was granted to students who ranked in the top 20% of their class. This year’s inductees included 4th and 5th year PharmD students as… |
![]() |
Varizig® for Chickenpox Symptoms...
January 1, 2013 - In the News / Politics By: Steve Soman, Co-Editor-in-Chief – Varicella Zoster Immune Globulin (Varizig®) was approved by the FDA on December 21st of 2012. The Canadian pharmaceutical company Cangene Corporation, which is owned in-part by Apotex Inc., markets the new product. The drug was approved by the Food and Drug Administration (FDA) to reduce “the severity of chicken pox… |
![]() |
New Healthcare Law Concerning Birth Control Causes Deba...
January 1, 2013 - Featured , In the News / Politics By: Katie Cimmino, Pharm D. Candidate c/o 2015 – With the start of the New Year the French government is enacting a new law concerning contraceptives. Now girls between the ages of 15 to 18 will be able to obtain free birth control. Not only will they have access to it, but the French government… |
![]() |
Adverse Events from Ingestion of OTC Eye Drops and Nasa...
December 1, 2012 - Featured , In the News / Politics By Tasnima Nabi, PharmD Candidate c/o 2016 – The FDA has issued warnings on accidental ingestion of over-the-counter eye drops and nasal sprays because they can cause serious harm in children at and under the age of five. Ingestion of as little as 0.6 ml of OTC nasal decongestants and redness-relief eye drops has been… |
![]() |
New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1 It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1 These patients tend to… |
![]() |
Ivacaftor (KalydecoTM): Targeting the Core of Cystic Fi...
November 1, 2012 - Clinical , Featured By: Eugene Kolomiyets, PharmD Candidate c/o 2013, AMSCOP at LIU – Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7.1 The disease has been linked to thousands of possible mutations, but only as many as 25-30 are tested for… |
![]() |
A New Frontier in Health Care: Digital Medicine...
October 1, 2012 - Professional Advice / Opinions By: Mahdieh Danesh Yazdi – We live in amazing times. Technology does not progress by steps anymore, it grows by leaps. Health-care has reaped the benefits of these advances just like any other industry. It was not a very long time ago that pharmacists would look up patient records in a book full of names… |
![]() |
Influenza Vaccines: Projected Strains for the 2012—20...
September 1, 2012 - Clinical , Featured By: Joo Hee Kwon, Pharm.D. Candidate c/o 2013 – There are 3 antigenic types of influenza: A, B, and C. Influenza C causes mild illness and therefore does not cause epidemics. In contrast, influenza A and B are capable of causing mild to severe flu and in some cases death. An epidemic can occur depending… |
![]() |
Bisphosphonates and Atypical Fracture Risk...
September 1, 2012 - Clinical , Featured By: Steve Soman, Pharm.D. Candidate c/o 2013 – Bisphosphonates are proven to enhance bone density and reduce fracture incidence in post-menopausal women but recent data suggests they may have adverse effects with regards to bone quality. The drugs in this class can be differentiated as non-nitrogen containing (older generation) and nitrogen containing (newer generation) medications.… |
![]() |
Student Spotlight: Felipe Camacho...
September 1, 2012 - Professional Advice / Opinions By Nandini Puranprashad, Pharm D. Candidate c/o 2013 – Felipe Camacho is a 6th year student at the University of Florida College of Pharmacy. He received his Bachelors of Arts in Music Composition from Rollins College, Winter Park, FL. After graduation, Mr. Camacho plans to pursue a residency at the Veterans Affairs (V.A.), Lee Memorial… |
![]() |
Brand Vs. Generic: What Every Prescriber Should Know...
September 1, 2012 - Clinical , Featured , Professional Advice / Opinions By: Marina Yermolayeva, PharmD Candidate c/o 2013 – “I’m allergic to the generic; I need the brand name medication,” is a common claim heard by many health care providers. Managed care organizations get numerous calls from doctors and patients requesting prior authorizations to approve brand name medications whilst there are generic alternatives available on formulary.… |
![]() |
Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug. First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing… |
![]() |
DIA 2012: St. John’s Students Collaborate to Innovate...
August 1, 2012 - Events , Professional Advice / Opinions By: Michael Cronin, Pharm.D. Candidate c/o 2014 – The Drug Information Association (DIA) student chapter at St. John’s University College of Pharmacy and Health Sciences began in March of 2012 to provide a local forum for cultivating awareness of opportunities within the pharmaceutical industry among doctor of pharmacy and allied health professions candidates. Within two… |
![]() |
An Experience That I Will Never Forget...
June 1, 2012 - Events , Professional Advice / Opinions By: Nancy Simon, Pharm.D. Candidate c/o 2016 – Exploring cities while getting lost, viewing beautiful sights, and eating delicious food: all highlights of my study abroad experience. This past semester was more than I ever expected; I do not even know where to begin. I participated in the Discover the World program through St. John’s… |
![]() |
Effect of Intravenous Ondansetron on QT Interval Prolon...
June 1, 2012 - Clinical By: Raymond Wu, Pharm.D. Candidate c/o 2013 The 5-hydroxytryptamine type 3 (5HT3) antagonists (e.g. ondansetron [Zofran®]) are commonly used in the prevention and treatment of nausea and vomiting in the inpatient setting.1 Overall, ondansetron is a well-tolerated medication with few side effects.1 Constipation, dizziness, and headache are the most commonly reported side effects associated… |
![]() |
Dr. Oz and Raspberry Ketones...
June 1, 2012 - Clinical , In the News / Politics , Professional Advice / Opinions By: Lila Ahmed, Pharm.D. Candidate c/o 2013 – Whether you wish to admit it or not, all of us have watched or at least heard of the Dr. Oz Show. I am sure that many of us encounter patients in the pharmacy who say, “I saw this on Dr. Oz; where could I find it?”… |
![]() |
Risk versus Benefit: Prescription to Over the Counter M...
June 1, 2012 - Professional Advice / Opinions By: Maria A. Sorbera, Pharm.D. Candidate c/o 2013 – Maria Sorbera was the 2011-2012 President of the Rho Chi Beta Theta Chapter at the Arnold & Marie Schwartz College of Pharmacy at Long Island University (LIU). She is a strong advocate of networking with fellow pharmacists regardless of their area of expertise, as well… |
![]() |
Lipid Panels: Fasting or Non-Fasting?...
April 1, 2012 - Clinical By: Nagma Gargi, Pharm D. Candidate 2013 – Traditionally, lipid panels are drawn under fasting conditions. Is there data supporting decreased accuracy in a non-fasting lipid panel? Cholesterol is an essential tool for our body for the synthesis of hormones, vitamin D, and bile acids. However, an excess of cholesterol pose a serious threat to… |
![]() |
Korlym® For Endogenous Cushing’s Syndrome...
April 1, 2012 - Clinical , In the News / Politics By: Alexandra Alleva, Pharm.D. Candidate c/o 2013 – On February 17, 2012, the US Food and Drug Administration (FDA) approved the first medication indicated specifically for patients with endogenous Cushing’s syndrome, a hormone disorder characterized by elevated blood levels of cortisol. Mifepristone (Korlym®) is for the treatment of glucose intolerance and Type 2 Diabetes Mellitus… |
![]() |
Eight Ways to Kick the Habit...
April 1, 2012 - Clinical , Professional Advice / Opinions By: Nagma Gargi, Pharm.D. Candidate c/o 2013 – Smoking cessation programs are extremely important in our society as increasing evidence emerges showing the correlation between smoking and the risk factors for various disease states. Thus as professionals it is our duty to educate ourselves first, then our patients. In this article, I want to discuss… |
![]() |
Counterfeit Prescription Medications: A Global Threat...
April 1, 2012 - Featured , In the News / Politics By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Counterfeit prescription medications are becoming a great concern for us. They have increased worldwide costs and endangered our public safety. Activities related to counterfeit drugs cost our healthcare system an estimated $75 billion in 2010. Many patients were seriously injured and died due to counterfeit medications.… |
![]() |
FDA Makes Label Changes to Statins...
March 1, 2012 - Clinical , In the News / Politics By: Mohamed Dungersi – On February 28, the U.S. Food and Drug Administration (FDA) approved important safety label changes for the class of cholesterol-lowering drugs known as statins. Aligned with the FDA’s goal to provide the public with more information for the safe and effective use of statins, the agency made several modifications to the… |
![]() |
Proton Pump Inhibitors and the Treatment of Osteoporosi...
February 1, 2012 - Clinical , Featured By: Neal Shah – Osteoporosis is a disease of the bone characterized by decreased bone mineral density (BMD), which reduces the ability of bone to provide adequate structural support. The main cause of this decreased BMD is inadequate calcium intake or absorption. The decreased BMD can cause diffuse lesions throughout the skeletal system and can… |
![]() |
The Latest Novartis Recalls...
February 1, 2012 - In the News / Politics By: Aleena Chacko, Long Island University Pharm.D. Candidate c/o 2013 – Established in 1996, Novartis International AG is a multinational pharmaceutical company based in Switzerland. On January 8, 2012, Novartis issued a recall on some popular over the counter (OTC) medications in the United States (U.S.) over concerns about broken or incorrect tablets ending up… |
![]() |
New Oral Direct Thrombin Inhibitors and Factor Xa Antic...
January 1, 2012 - Clinical , Featured , In the News / Politics By: Neal Shah – Anticlotting agents are staples in the prevention and treatment of thrombotic disorders, such as deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction, and atrial fibrillation.1 Intravenous medications, such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct thrombin inhibitors (DTI), are commonly used in, both, inpatient and outpatient settings.… |
![]() |
FDA Challenges Pharmacists’ Right to Compound...
January 1, 2012 - Featured , In the News / Politics By: Ebey P. Soman – With clearly established roles for pharmacists, compounding is recognized and upheld as a core foundation of the pharmacy profession. It allows pharmacists to provide unique and tailored medication regimens for their patients. The U.S. Food and Drug Administration (FDA) thought otherwise when the agency sued Franck’s Lab, Inc., a Florida-based… |
![]() |
Partners in Health Comes to Columbia University...
January 1, 2012 - Events By: Bethsy Jacob, Pharm.D. Candidate c/o 2014 – On November 16, 2011, Dr. Joia Mukherjee, Medical Director of Partners in Healthcare (PIH), presented for GlobeMed at Columbia University. Manzi Anatole, a hired nurse in Rwanda, accompanied Dr. Mukherjee. Along with a handful of her students, Dr. Joanne Carroll arranged a trip to the open event. … |
![]() |
Differences Between Antagonists and Inverse Agonists...
December 1, 2011 - Clinical By: Neal Shah – There are two major classifications of drug-receptor activity: agonism and antagonism. Agonism occurs when a molecule binds to a receptor, causes an exertion of normal receptor operation, and eventually causes a response. Antagonism of a receptor occurs when a molecule binds to the receptor and does not allow activity to occur.1… |
![]() |
Finding Your Niche in Pharmacy...
December 1, 2011 - Professional Advice / Opinions By: Nandini Puranprashad – As primary advocators of patient care, student pharmacists and pharmacists are well on their way in changing the public’s impression of us staying behind the counter at the corner drugstore doing nothing but “counting, licking, and sticking.” It is time to step out of the classroom and from behind the counters… |
![]() |
Drug Shortages: Impacts and Prevention Measures...
December 1, 2011 - Featured , In the News / Politics , Professional Advice / Opinions By: Jimmy Johnson, PharmD Candidate c/o 2012 – Drug shortages have become more and more of an issue in the health care industry. There are over 200 drugs on the Food and Drug Administration’s (FDA) drug shortage list – a number that has tripled in the last five years.1 The largest impact has been on anesthesia… |
![]() |
Faculty Spotlight: Dr. Charles R. Ashby...
December 1, 2011 - Featured , Professional Advice / Opinions By: Neal Shah – Dr. Ashby is a well-known Pharmacology professor for student pharmacists studying in their professional years. He graduated from the University of Louisville with a BA in Biology and Psychology in 1983. After obtaining his PhD in Pharmacology from the University of Louisville in 1987, he continued his education by obtaining a… |
![]() |
Federal Government to Attempt Limiting Drug Shortages...
December 1, 2011 - In the News / Politics By: Mahdieh Danesh Yazdi, with special thanks to Dr. Tomasz Jodlowski – Drug shortages have plagued health care institutions in recent years; they present a serious problem to health care delivery on a national scale. In 2004, there were 58 drug shortages; now, in 2011, this number has increased to 198. Due to limited access… |
![]() |
Pharmacogenetic Applications in Clinical Practice...
November 1, 2011 - Clinical , Featured By: Neal Shah – The focus of pharmacy is rapidly shifting from simple filling and dispensing of prescriptions to preventative medicine and efficient clinical practice. The field of genetics has been incorporated in many defining therapies and will continue to shape how we treat our patients. Examples discussed here are the roles of human leukocyte… |
![]() |
In The News: TNF-Alpha Inhibitors Receive More Warnings...
October 1, 2011 - In the News / Politics By Ebey P. Soman – TNF-alpha inhibitors are drugs used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, as well as other disease states. These agents suppress the immune system and increase the risk of developing serious infections. Currently, there are five approved drugs in this category: • Adalimumab (Humira®, Abbott) • Certolizumab pegol… |